GE HealthCare insider trading
Every open-market purchase and sale by GE HealthCare's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following GE HealthCare’s insiders pay?
From March 16, 2023 to May 26, 2026, 16 insiders reported 10 open-market purchases and 10 sales not made under a pre-set plan in GE HealthCare. Twelve months after each purchase was reported, the shares were −19.9% against the S&P 500 on average (median −19.9%), over 2 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −24.8% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 27, 2023 into $14,134 by November 2, 2026, +10.1% a year. It held shares 70% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $16,490 (+15.0% a year), and held throughout $19,927 (+21.2%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Culp H Lawrence Jr | Director | 2 | −15.4% (1) | 0% | 0 | — | May 7, 2026 |
| Jimenez Frank R | GC & Corporate Secretary | 2 | −24.4% (1) | 0% | 0 | — | April 30, 2026 |
| Makela Jan | CEO, Imaging | 0 | — | — | 2 | −19.7% (2) | May 15, 2024 |
| Rott Roland | CEO, Imaging | 0 | — | — | 2 | −29.9% (2) | November 6, 2024 |
| Arduini Peter J | President and CEO | 1 | — | — | 0 | — | April 30, 2026 |
| Hochman Rodney F | Director | 1 | — | — | 0 | — | May 13, 2026 |
| Kass-Hout Taha | Chief Technology Officer | 0 | — | — | 1 | −24.8% (1) | May 29, 2024 |
| Lobo Kevin | Director | 1 | — | — | 0 | — | May 26, 2026 |
| Newcomb George A. | Chief Accounting Officer | 0 | — | — | 1 | −21.9% (1) | February 19, 2025 |
| O'neill Kevin Michael | CEO, PDx | 0 | — | — | 1 | −9.5% (1) | August 2, 2023 |
| Rackliffe Philip | CEO, AVS | 0 | — | — | 1 | −31.9% (1) | November 5, 2024 |
| Saccaro James | Chief Financial Officer | 1 | — | — | 0 | — | May 1, 2026 |
| Stacherski Kenneth R. | Ch. Supply Chain & Serv. Ofc. | 0 | — | — | 1 | −29.3% (1) | August 15, 2024 |
| Stromberg William J | Director | 1 | — | — | 0 | — | May 7, 2026 |
| Westrick Thomas J. | CEO, Patient Care Solutions | 0 | — | — | 1 | −32.1% (1) | August 7, 2024 |
| Yang Watkin Phoebe L. | Director | 1 | — | — | 0 | — | May 11, 2026 |
When several insiders traded GE HealthCare
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of GE HealthCare in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| May 29, 2026 | 8 buying | +13.2% | not yet | not yet |